focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.30
Bid: 7.25
Ask: 7.35
Change: 0.00 (0.00%)
Spread: 0.10 (1.379%)
Open: 7.30
High: 7.30
Low: 7.30
Prev. Close: 7.30
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Correction to the Form of Proxy

15 Dec 2009 15:12

RNS Number : 1597E
Phytopharm PLC
15 December 2009
 

Correction to the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting, each dated 3 December 2009

Phytopharm plc (the "Company")

In the summaries of the resolutions to be voted on at the general meeting of the Company at 11.00am on 29 December 2009 at the offices of KBC Peel Hunt Ltd, 111 Old Broad Street, London EC2N 1PH, it has been noted that in the Form of Proxy for Holders of Ordinary Shares, Form of Direction - Share Incentive Plan 2007 and Form of Direction to Exercise Voting Rights - General Meeting dated 3 December 2009 (the "Forms"), the summary of resolution 2 refers to shares being issued to an aggregate nominal value of £25,212,904.20 rather than £2,521,290.42; and the summary of resolution 4 refers to a subscription price of £0.01 rather than £0.10.  All other details in the Forms and all details in the notice of general meeting remain unchanged. 

The full text of each of these amended resolution summaries is set out below: "2.  To authorise the Directors for the purposes of section 551 of the Act to exercise all the powers of the Company to allot and grant rights to subscribe for or to convert securities into shares of the Company up to an aggregate nominal amount of £2,521,290.42 pursuant to or in connection with the Placing and Open Offer." "4. To approve the issue of Ordinary Shares pursuant to the Placing and Open Offer at a subscription price of £0.10 each (representing a discount of approximately 33.3 per cent. to the closing middle market price for an Ordinary Share for the business day immediately preceding the date on which the Company announced such price)."

For further information contact:

Phytopharm plc

Tel: +44 (0)1480 437 697

Sandy Morrison (Acting CEO)

Keith Thomson (Interim COO)

Alistair Taylor (Non-executive Chairman)

KBC Peel Hunt Ltd (Sponsor, Broker & Underwriter)

Tel: +44 (0)20 7418 8900

Capel Irwin / Matt Goode (Corporate Finance)

Marianne Woods / Dan Webster (Corporate Broking)

Notes:

Phytopharm is listed on the Official List of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com.

KBC Peel Hunt Ltd, which is regulated by the FSA, is acting as Sponsor, Broker and Underwriter for the Company and is not acting for any other person and will not be responsible to any other person for providing the protections afforded to clients of KBC Peel Hunt Ltd or for providing advice in relation to the Placing and Open Offer, Admission or any other arrangements referred to herein.

This announcement has been issued by, and is the sole responsibility of, Phytopharm. Apart from the responsibilities and liabilities, if any, which may be imposed by FSMA, KBC Peel Hunt Ltd nor any of its affiliates, parent undertakings, subsidiary undertakings or subsidiaries of its parent undertakings or any of its respective directors, officers, employees or advisers or any other person accepts any responsibility whatsoever and makes no representation or warranty, express or implied, for or in respect of the contents of this announcement or as to the accuracy or completeness or fairness of the information or opinions contained in this announcement and, without prejudice to the generality of the foregoing, no responsibility or liability is accepted by any of them for any such information or opinions or for any errors or omissions. 

This announcement does not constitute an offer to sell or an invitation or solicitation to purchase or subscribe for any securities. The Placing and Open Offer will be made solely by the Prospectus which will contain the full terms and conditions of the Placing and Open Offer, including details of how the Placing and Open Offer may be accepted. Any acceptance or other response in relation to the Placing and Open Offer should be made only on the basis of the information contained in the Prospectus.

Any New Ordinary Shares issued or to be issued pursuant to the Prospectus have not been and will not be registered under the US Securities Act, or any relevant securities laws of any state of the United States. Subject to certain exceptions, such New Ordinary Shares may not be offered, sold or delivered in the United States or to or for the account or benefit of U.S. persons, as such terms are defined in Regulation S under the US Securities Act.

Definitions:

The following definitions apply throughout this announcement, unless the context requires otherwise:

"Admission"
the admission of the New Ordinary Shares (i) to the Official List and (ii) to trading on the London Stock Exchange's main market for listed securities becoming effective in accordance with, respectively LR 3.2.7G of the Listing Rules and paragraph 2.1 of the Admission and Disclosure Standards
 
 
"Admission and Disclosure Standards"
the requirements contained in the publication dated 7 September 2009
 
 
"Existing Ordinary Shares"
the 94,548,381 existing ordinary shares of 1 pence each in nominal value in the capital of the Company as at 3 December 2009
 
 
"Financial Services Authority"or "FSA"
the UK Financial Services Authority
 
 
"FSMA"
the Financial Services and Markets Act 2000 (as amended) and all regulations promulgated thereunder from time to time
 
 
"Listing Rules"
the listing rules made by the FSA in exercise of its function as competent authority pursuant to Part VI of FSMA
 
 
"London Stock Exchange"
London Stock Exchange plc
 
 
"New Ordinary Shares"
the 252,129,042 new Ordinary Shares of 1p each in nominal value in the capital of the Company proposed to be issued under the Placing and Open Offer
 
 
"Official List"
the Official List of the FSA
 
 
"Open Offer"
the conditional invitation to Qualifying Shareholders to apply for up to 252,129,042 New Ordinary Shares at the Offer Price on a pre-emptive basis
 
 
"Ordinary Share"
ordinary shares in the capital of the Company from time to time
 
 
"Overseas Shareholders"
Qualifying Shareholders who have registered addresses outside the United Kingdom
 
 
"Placing"
the conditional placing by KBC Peel Hunt of 172,090,285 New Ordinary Shares, subject to clawback pursuant to the Open Offer, on behalf of the Company on the terms and subject to the conditions contained in the Placing Agreement
 
 
"Placing Agreement"
the placing and open offer agreement dated 3 December 2009 between KBC Peel Hunt and the Company relating to the Placing and Open Offer
 
 
"Prospectus"
the prospectus in relation to the Placing and Open Offer dated 3 December 2009
 
 
"Qualifying Shareholders"
holders of Existing Ordinary Shares on the register of members of the Company on the Record Date (other than certain Overseas Shareholders)
 
 
"Record Date"
30 November 2009
 
 
"Shareholder"
a holder of Existing Ordinary Shares(s)
 
 
"US", "USA" or "United States"
 the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia
 
 
"US Securities Act"
the United States Securities Act of 1933, as amended

All references to "pounds", "pounds sterling", "Sterling", "£", "pence", "penny" and "p" are to the lawful currency of the United Kingdom.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEELFFKLBBFBX
Date   Source Headline
29th Aug 201312:01 pmRNSSchedule 1 update - Phytopharm plc
9th Aug 20137:00 amRNSInterim Management Statement
8th Aug 201312:23 pmRNSSchedule 1 update - Phytopharm plc
8th Aug 201311:00 amRNSChange to AIM Admission Timetable
6th Aug 20132:15 pmRNSSchedule 1 - Phytopharm plc
5th Aug 20132:16 pmRNSResult of General Meeting
19th Jul 201311:06 amRNSCancellation of Listing and Admission to AIM
23rd May 20137:00 amRNSInterim Results
21st May 20137:45 amRNSStatement re. Suspension
21st May 20137:30 amRNSTemporary Suspension - Phytopharm Plc
17th May 20139:23 amRNSNotice of Results
27th Mar 201310:15 amRNSAGM Statement
26th Mar 20137:00 amRNSStrategic Review Update
15th Mar 201312:06 pmRNSHolding(s) in Company
18th Feb 20137:00 amRNSResearch Update
13th Feb 20131:59 pmRNSHolding(s) in Company
5th Feb 20137:00 amRNSInterim Management Statement
4th Feb 201311:34 amRNSNotice of AGM
19th Dec 20129:21 amRNSAnnual Financial Report
18th Dec 20127:00 amRNSCogane in ALS Update
17th Dec 201211:00 amRNSBlocklisting Interim Review
22nd Nov 20127:00 amRNSPreliminary Results
9th Nov 20121:32 pmRNSNotice of Results
5th Nov 20121:00 pmRNSBlocklisting Interim Review
17th Oct 20125:27 pmRNSBlocklisting Interim Review
1st Oct 201211:44 amRNSTotal Voting Rights
26th Sep 20127:00 amRNSHolding(s) in Company
31st Aug 20124:40 pmRNSSecond Price Monitoring Extn
31st Aug 20124:35 pmRNSPrice Monitoring Extension
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
16th Aug 20127:00 amRNSInterim Management Statement
18th Jun 20129:59 amRNSBlocklisting Interim Review
30th May 20127:00 amRNSHalf Yearly Report
11th May 20127:00 amRNSResearch Update
3rd May 201211:46 amRNSNotice of Results
3rd May 20129:54 amRNSBlocklisting Interim Review
18th Apr 20127:00 amRNSResearch Update
18th Apr 20127:00 amRNSResearch Update
11th Apr 201211:08 amRNSBlock Listing Application
29th Mar 20127:00 amRNSDirectorate Change
28th Mar 20129:35 amRNSResult of AGM
24th Feb 20127:00 amRNSNotice of AGM
16th Feb 20127:00 amRNSInterim Management Statement
14th Feb 20129:34 amRNSHolding(s) in Company
6th Feb 20129:25 amRNSAnnual Information Update
2nd Feb 20127:00 amRNSDirectorate Change
27th Jan 201210:17 amRNSAnnual Financial Report
16th Jan 20127:00 amRNSResearch Update
11th Jan 20123:53 pmRNSBlocklisting Interim Cancellation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.